Related references
Note: Only part of the references are listed.Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder
F. Kasteng et al.
ACTA PSYCHIATRICA SCANDINAVICA (2011)
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Kathleen R. Merikangas et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study
Ronald Marcus et al.
BIPOLAR DISORDERS (2011)
One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis
Edward Kim et al.
BMC PSYCHIATRY (2011)
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors
Yoshihiro Tadori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Aripiprazole for the treatment of bipolar disorder: a review of current evidence
Andrea Fagiolini et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
Andrea Cipriani et al.
LANCET (2011)
Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole
Maria Sierra Pena et al.
MOVEMENT DISORDERS (2011)
Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
Ayseguel Yildiz et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
Alexander C. Tsai et al.
PLOS MEDICINE (2011)
Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder
Yonghua Jing et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study
Eduard Vieta et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007)
Rif S. El Mallakh et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania
Maria Mavrikaki et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial
David E. Kemp et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials
John M. Kane et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Epidemiologic study of aripiprazole use and the incidence of suicide events
Marianne Ulcickas Yood et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
David Muzina
Neuropsychiatric Disease and Treatment (2010)
Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis
Konstantinos N Fountoulakis et al.
Annals of General Psychiatry (2010)
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
Lakshmi N. Yatham et al.
BIPOLAR DISORDERS (2009)
Antipsychotic agents in the treatment of bipolar mania
Mauricio Tohen et al.
BIPOLAR DISORDERS (2009)
The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments
Felicity Ng et al.
BIPOLAR DISORDERS (2009)
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Allan H. Young et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Time to Psychiatric Hospitalization in Patients With Bipolar Disorder Treated With a Mood Stabilizer and Adjunctive Atypical Antipsychotics: A Retrospective Claims Database Analysis
Edward Kim et al.
CLINICAL THERAPEUTICS (2009)
Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study
P. E. Keck et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology
G. M. Goodwin
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania
Heinz Grunze et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2009)
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone
Yonghua Jing et al.
JOURNAL OF MEDICAL ECONOMICS (2009)
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia:: An [18F]fallypride PET study
Gerhard Gruender et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: A placebo-controlled study
Eduard Vieta et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Intramuscular aripiprazole - A review of its use in the management of agitation in schizophrenia and bipolar I disorder
Mark Sanford et al.
CNS DRUGS (2008)
Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors
Yoshihiro Tadori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Proposed strategies for successful clinical management with aripiprazole
Rajnish Mago
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study
D. J. Muzina et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder
Trisha Suppes et al.
JOURNAL OF AFFECTIVE DISORDERS (2008)
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms - Young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials
Mark A. Frye et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Dose-Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F] Fallypride
Lawrence S. Kegeles et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
H. A. Nasrallah
MOLECULAR PSYCHIATRY (2008)
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo
Paul E. Keck et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia:: A triple tracer PET study
David Mamo et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling
Shaun Jordan et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling
Shaun Jordan et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors:: functional receptor-binding and in vivo electrophysiological studies
Arlene D. Stark et al.
PSYCHOPHARMACOLOGY (2007)
Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline
Gary S. Sachs et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials
Lesley A. Smith et al.
BIPOLAR DISORDERS (2007)
Atypical Antipsychotics for the treatment of bipolar disorder - More shadows than lights
Salvatore Gentile
CNS DRUGS (2007)
Long-term use of atypical antipsychotics in bipolar disorder
Megan J. Ehret et al.
PHARMACOTHERAPY (2006)
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study
Gary Sachs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials
RH Perlis et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder
Paul E. Keck et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine
M Tohen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Emerging treatments for bipolar disorder: Safety and adverse effect profiles
PA Marken et al.
ANNALS OF PHARMACOTHERAPY (2006)
Aripiprazole:: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia
G Gründer et al.
PHARMACOPSYCHIATRY (2006)
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors:: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist
ES Burstein et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex
A Zocchi et al.
NEUROSCIENCE LETTERS (2005)
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania - Double-blind, randomised, comparative 12-week trial
E Vieta et al.
BRITISH JOURNAL OF PSYCHIATRY (2005)
Pharmacokinetics of aripiprazole and concomitant lithium and valproate
L Citrome et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Atypical antipsychotics: newer options for mania and maintenance therapy
E Vieta et al.
BIPOLAR DISORDERS (2005)
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal, healthy volunteers
S Mallikaarjun et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain
Z Li et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
PE Keck et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology
DA Shapiro et al.
NEUROPSYCHOPHARMACOLOGY (2003)
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder
CL Bowden et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597):: A study using positron emission tomography and [11C]raclopride
F Yokoi et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
KD Burris et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
S Jordan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Share Paper
